K562 Cells
Insights on K562 cells
Description | The K562 cell line, originating from the bone marrow of a 53-year-old female with chronic myelogenous leukemia, serves as a cornerstone in various research fields such as immunology, tumor immunology, and immune system disorder research. Human K-562 cells are widely used in studies involving immune system interactions, particularly with effector cells like natural killer cells (NK). This is due to their unique characteristics, such as the expression of specific antigens that can be recognized by NK cells. Exploring the interaction between NK cells and cancerous cell lines like K562 offers insights into immune defense mechanisms. NK cells' ability to recognize and respond to K562 cells varies with the presence of specific markers, which fluctuate throughout the K562 cell cycle. K562 cells are characterized by the presence of the Philadelphia chromosome, which results from a translocation between chromosomes 9 and 22, creating the BCR-ABL fusion gene. This fusion gene is not a normal ABL transcript but a mutated form that is constitutively active and leads to uncontrolled cell proliferation. Analyzing ABL transcripts in K562 cells sheds light on leukemia's molecular dynamics and immune evasion strategies. K562 cells are crucial for understanding the cell cycle, particularly for analyzing cell cycle phases and distributions. This analysis is essential for evaluating the impact of ABL gene expression and the associated decrease in ABL fusion transcripts. Furthermore, K562 cells are valuable in assays assessing the cytotoxic effects of FGFR inhibitors and the activity of epigenetic enzymes, highlighting their significance in elucidating cell signaling pathways and the mechanisms of action of various therapeutic agents. The versatility of K562 cells, ranging from their role in enzyme activity assays to their application in immunological studies with natural killer (NK) cells, emphasizes their widespread utility in the scientific realm. This adaptability highlights their significance in bridging the gap between fundamental research and translational medicine, playing a crucial role in advancing the fight against chronic myelogenous leukemia. |
---|---|
Organism | Human |
Tissue | Bone marrow |
Disease | Chronic myeloid leukemia |
Synonyms | K562, K.562, K 562, KO, GM05372, GM05372E |
Details
Age | 53 years |
---|---|
Gender | Female |
Ethnicity | Caucasian |
Morphology | Round cells |
Cell type | Lymphoblast |
Growth properties | Suspension |
Documentation
Citation | K562 (Cytion catalog number 300224) |
---|---|
Biosafety level | 1 |
Genotype of the human K562 cell line
Antigen expression | CD7 (25%) |
---|---|
Isoenzymes | G6PD, B, AK-1, 1, ES-D, 1, GLO-1, 2, PGM1, 0, PGM3, 1, Me-2, 0 |
Oncogenes | BCR-ABL1 |
Tumorigenic | Yes, in nude mice. |
Reverse transcriptase | Negative |
Handling
Culture Medium | RPMI 1640, w: 2.1 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
---|---|
Medium supplements | Supplement the medium with 10% FBS |
Subculturing | Maintain cultures by periodically adding or replacing the medium. Initiate cultures with a density of 2 x 10^5 cells/ml and keep the cell concentration within the range of 1 x 10^5 to 1 x 10^6 cells/ml for optimal growth. |
Seeding density | 1 x 10^5 cells/ml |
Fluid renewal | Every 2 days |
Freezing recovery | Please allow cells to recover for roughly 24 to 48 hours after thawing. |
Freeze medium | CM-1 (Cytion catalog number 800100) or CM-ACF (Cytion catalog number 806100) |
Handling of cryopreserved cultures |
|
Quality assurance
Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
---|---|
STR profile |
Amelogenin: x,x
CSF1PO: 9,10
D13S317: 8
D16S539: 11,12
D5S818: 11,12
D7S820: 9,11
TH01: 9.3
TPOX: 8,9
vWA: 16
D3S1358: 16
D21S11: 29,30
D18S51: 15
Penta E: 5,14
Penta D: 9,13
D8S1179: 12
FGA: 21,24
D1S1656: 15,16
D6S1043: 11,15
D2S1338: 17
D12S391: 23
D19S433: 14,14.2
|
HLA alleles |
A*: 11:01:01, 31:01:02
B*: 18:01:01, 40:01:02
C*: 03:04:01, 05:01:01
DRB1*: 03:01:01, 04:04:01
DQA1*: 03:01:01, 05:01:01
DQB1*: 02:01:01, 03:02:01
DPB1*: 04:01:01G, 04:02:01G
E: 01:03:02
|